Back to top

Viridian Therapeutics (VRDN) Receives a Rating Update from a Top Analyst

In a report released today, Faisal Khurshid from Jefferies maintained a Buy rating on Viridian Therapeutics, with a price target of $30.00. Accordi...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Viridian Therapeutics, Inc. (VRDN)